

ARTWORK/PACKAGING/PRODUCTION			
File Name:	8SEL029_Selaspot_Insert		
Artwork Date:	September 18, 2020	Version	v.1 REV 09/20
Item Size:	12.25"(h) x 10.75"(w)		
Dieline:	No./Name		
<input checked="" type="checkbox"/> CMYK	<input type="checkbox"/> Scale:	100%	
<input type="checkbox"/> CMYK + SPOT	Label	<input type="checkbox"/> Carton	<input checked="" type="checkbox"/> Insert
<input type="checkbox"/> SPOT COLORS (Pantone)	Content Smallest Font	8 pt	
<input checked="" type="checkbox"/> PMS (Black 100%)	Registration Smallest Font:	6 pt	
<input type="checkbox"/> PMS	Verified Dieline	<input type="checkbox"/> Y	<input type="checkbox"/> N
<input type="checkbox"/> PMS	Verified Batch Area	<input type="checkbox"/> Y	<input type="checkbox"/> N
<input type="checkbox"/> PMS	Mock-Up Approved	<input type="checkbox"/> Y	<input type="checkbox"/> N
<input type="checkbox"/> ONINSERT	<input type="checkbox"/> COPY LIMIT	<input type="checkbox"/> DIELINE	
<input type="checkbox"/> BLEED LIMIT	<input type="checkbox"/> ONINSERT PLACEMENT TOLERANCE	<input type="checkbox"/> NO VARNISH	
	Unwind #	<input type="checkbox"/> 1	<input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4

SelaSpot™ (selamectin) Topical Parasiticide For Dogs and Cats

CAUTION:

US Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

SelaSpot (selamectin) Topical Parasiticide is available as a colorless to yellow, ready to use solution in single dose tubes for topical (dermal) treatment of dogs six weeks of age and older and cats eight weeks of age and older. The content of each tube is formulated to provide a minimum of 2.7 mg/lb (6 mg/kg) of body weight of selamectin. The chemical composition of selamectin is (5Z,25S)-25-cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-hydroxyiminoavermectin A_{1a}.

INDICATIONS:

SelaSpot is recommended for use in dogs six weeks of age or older and cats eight weeks of age and older for the following parasites and indications:

Dogs:

SelaSpot kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations (*Ctenocephalides felis*), prevention of heartworm disease caused by *Dirofilaria immitis*, and the treatment and control of ear mite (*Otodectes cynotis*) infestations. SelaSpot also is indicated for the treatment and control of sarcoptic mange (*Sarcoptes scabiei*) and for the control of tick infestations due to *Dermacentor variabilis*.

Cats:

SelaSpot kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations (*Ctenocephalides felis*), prevention of heartworm disease caused by *Dirofilaria immitis*, and the treatment and control of ear mite (*Otodectes cynotis*) infestations. SelaSpot is also indicated for the treatment and control of roundworm (*Toxocara cati*) and intestinal hookworm (*Ancylostoma tubaeforme*) infections in cats.

WARNINGS:

Not for human use. Keep out of the reach of children.

In humans, SelaSpot may be irritating to skin and eyes. Reactions such as hives, itching and skin redness have been reported in humans in rare instances. Individuals with known hypersensitivity to SelaSpot should use the product with caution or consult a health care professional. SelaSpot contains isopropyl alcohol and the preservative butylated hydroxytoluene (BHT). Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If contact with eyes occurs, then flush eyes copiously with water. In case of ingestion by a human, contact a physician immediately. The safety data sheet (SDS) provides more detailed occupational safety information. For a copy of the SDS or to report adverse reactions attributable to exposure to this product, call 1-888-524-6332.

Flammable - Keep away from heat, sparks, open flames or other sources of ignition.

Do not use in sick, debilitated or underweight animals (see SAFETY).

PRECAUTIONS:

Prior to administration of SelaSpot, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. SelaSpot is not effective against adult *D. immitis* and, while the number of circulating microfilariae may decrease following treatment, SelaSpot is not effective for microfilariae clearance.

Hypersensitivity reactions have not been observed in dogs with patent heartworm infections administered three times the recommended dose of selamectin. Higher doses were not tested.

ADVERSE REACTIONS:

Pre-approval clinical trials:

Following treatment with selamectin, transient localized alopecia with or without inflammation at or near the site of application was observed in approximately 1% of 691 treated cats. Other signs observed rarely (<0.5% of 1743 treated cats and dogs) included vomiting, loose stool or diarrhea with or without blood, anorexia, lethargy, salivation, tachypnea, and muscle tremors.

Post-approval experience:

In addition to the aforementioned clinical signs that were reported in pre-approval clinical trials, there have been reports of pruritus, urticaria, erythema, ataxia, fever, and rare reports of death. There have also been rare reports of seizures in dogs (see **WARNINGS**).

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>.

DOSAGE:

The recommended minimum dose is 2.7 mg selamectin per pound (6 mg/kg) of body weight.

Administer the entire contents of a single dose tube (or two tubes used in combination for dogs weighing over 130 pounds) of SelaSpot topically in accordance with the following tables. (See **ADMINISTRATION** for the recommended treatment intervals.)

Cats (lb)	Package Color	mg per tube	Potency (mg/mL)	Administered volume (mL)
Up to 5	Mauve	15 mg	60	0.25
5.1 - 15	Blue	45 mg	60	0.75
15.1 - 22	Taupe	60 mg	60	1.0

For cats over 22 lbs use the appropriate combination of tubes.

Dogs (lb)	Package Color	mg per tube	Potency (mg/mL)	Administered volume (mL)
Up to 5	Mauve	15 mg	60	0.25
5.1 - 10	Purple	30 mg	120	0.25
10.1 - 20	Brown	60 mg	120	0.5
20.1 - 40	Red	120 mg	120	1.0
40.1 - 85	Teal	240 mg	120	2.0
85.1 - 130	Plum	360 mg	120	3.0

For dogs over 130 lbs use the appropriate combination of tubes.

Recommended for use in dogs 6 weeks of age and older and in cats 8 weeks of age and older.

ADMINISTRATION:

A veterinarian or veterinary technician should demonstrate or instruct the pet owner regarding the appropriate technique for applying SelaSpot topically to dogs and cats prior to first use.

Firmly press the cap down to puncture the seal on the SelaSpot tube; a clicking sound will confirm that the cap has successfully punctured the seal. Remove the cap and check to ensure that the tip of the tube is open. To administer the product, part the hair on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the tube on the skin and squeeze the tube 3 or 4 times to empty its entire contents directly onto the skin in one spot. Keeping the tube squeezed, drag it away from the liquid and lift to remove. Check the tube to ensure that it is empty. Do not massage the product into the skin. Due to alcohol content, do not apply

to broken skin. Avoid contact between the product and fingers. Do not apply when the haircoat is wet. Bathing or shampooing the dog 2 or more hours after treatment will not reduce the effectiveness of SelaSpot against fleas or heartworm. Bathing or shampooing the cat 2 hours after treatment will not reduce the effectiveness of SelaSpot against fleas. Bathing or shampooing the cat 24 hours after treatment will not reduce the effectiveness of SelaSpot against heartworm. Stiff hair, clumping of hair, hair discoloration, or a slight powdery residue may be observed at the treatment site in some animals. These effects are temporary and do not affect the safety or effectiveness of the product. Discard empty tubes in your ordinary household refuse.

Flea Control in Dogs and Cats

For the prevention and control of flea infestations, SelaSpot should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. In controlled laboratory studies >98% of fleas were killed within 36 hours. Results of clinical field studies using selamectin monthly demonstrated >90% control of flea infestations within 30 days of the first dose. Dogs and cats treated with selamectin, including those with pre-existing flea allergy dermatitis, showed improvement in clinical signs associated with fleas as a direct result of eliminating the fleas from the animals and their environment.

If the dog or cat is already infested with fleas when the first dose of SelaSpot is administered, adult fleas on the animal are killed and no viable fleas hatch from eggs after the first administration. However, an environmental infestation of fleas may persist for a short time after beginning treatment with SelaSpot because of the emergence of adult fleas from pupae.

Heartworm Prevention in Dogs and Cats

For the prevention of heartworm disease, SelaSpot must be administered on a monthly basis. SelaSpot may be administered year-round or at least within one month after the animal's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of SelaSpot and resumption of monthly dosing will minimize the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of SelaSpot must be given within a month of the last dose of the former medication.

Selamectin, the active ingredient in SelaSpot, is a macrocyclic lactone compound. These compounds effectively prevent the development of adult heartworms when administered to dogs and cats within one month of exposure to infective (*L.*) *Dirofilaria immitis* larvae. Efficacy of macrocyclic lactones decreases below 100% in dogs, however, if first administered >2 months after exposure to infective larvae. Thus, in heartworm endemic regions, delaying initiation of heartworm prevention using SelaSpot beyond 2 months of first exposure to infective larvae (e.g., starting puppies and kittens at >8 weeks of age), or gaps of >2 months in the administration of SelaSpot during periods of heartworm transmission, increases the risk of the animal acquiring heartworms. Animals with unknown heartworm history that test negative for heartworms prior to the initiation of SelaSpot may be harboring pre-patent infections at the time SelaSpot was started. Testing such animals 3-4 months after initiation of SelaSpot would be necessary to confirm their negative heartworm status.

At the discretion of the veterinarian, cats ≥6 months of age may be tested to determine the presence of existing heartworm infections before beginning treatment with SelaSpot. Cats already infected with adult heartworms can be given SelaSpot monthly to prevent further infections.

Ear Mite Treatment in Dogs and Cats

For the treatment of ear mite (*O. cynotis*) infestations in dogs and cats, SelaSpot should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of SelaSpot will control any subsequent ear mite infestations. In the clinical field trials ears were not cleaned, and many animals still had debris in their ears after the second dose. Cleansing of the infested ears is recommended to remove the debris.

Sarcoptic Mange Treatment in Dogs

For the treatment of sarcoptic mange (*S. scabiei*) in dogs, SelaSpot should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of SelaSpot will control any subsequent sarcoptic mange mite infestations. Because of the difficulty in finding sarcoptic mange mites on skin scrapings, effectiveness assessments also were based on resolution of clinical signs. Resolution of the pruritus associated with the mite infestations was observed in approximately 50% of the dogs 30 days after the first treatment and in approximately 90% of the dogs 30 days after the second monthly treatment.

Tick Control in Dogs

For the control of tick (*Dermacentor variabilis*) infestations in dogs, SelaSpot should be administered on a monthly basis. In heavy tick infestations, complete efficacy may not be achieved after the first dose. In these cases, one additional dose may be administered two weeks after the previous dose, with monthly dosing continued thereafter.

Nematode Treatment in Cats

For the treatment and control of intestinal hookworm (*A. tubaeforme*) and roundworm (*T. cati*) infections, SelaSpot should be applied once as a single topical dose.

SAFETY:

Selamectin has been tested safe in over 100 different pure and mixed breeds of healthy dogs and over 15 different pure and mixed breeds of healthy cats, including pregnant and lactating females, breeding males and females, puppies six weeks of age and older, kittens eight weeks of age and older, and avermectin-sensitive collies. A kitten, estimated to be 5-6 weeks old (0.3 kg), died 8 ½ hours after receiving a single treatment of selamectin at the recommended dosage. The kitten displayed clinical signs which included muscle spasms, salivation and neurological signs. The kitten was a stray with an unknown history and was malnourished and underweight (see **WARNINGS**).

DOGS: In safety studies, selamectin was administered at 1, 3, 5, and 10 times the recommended dose to six-week-old puppies, and no adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of selamectin at the recommended topical dose in 5- to 8-month-old beagles did not cause any adverse reactions. In a pre-clinical study selamectin was dosed orally to ivermectin-sensitive collies. Oral administration of 2.5, 10, and 15 mg/kg in this dose escalating study did not cause any adverse reactions; however, eight hours after receiving 5 mg/kg orally, one avermectin-sensitive collie became ataxic for several hours, but did not show any other adverse reactions after receiving subsequent doses of 10 and 15 mg/kg orally. In a topical safety study conducted with avermectin-sensitive collies at 1, 3 and 5 times the recommended dose of selamectin, salivation was observed in all treatment groups, including the vehicle control. Selamectin also was administered at 3 times the recommended dose to heartworm infected dogs, and no adverse effects were observed.

CATS: In safety studies, selamectin was applied at 1, 3, 5, and 10 times the recommended dose to six-week-old kittens. No adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of the recommended topical dose of selamectin to cats caused salivation and intermittent vomiting. Selamectin also was applied at 4 times the recommended dose to patent heartworm infected cats, and no adverse reactions were observed.

In well-controlled clinical studies, selamectin was used safely in animals receiving other frequently used veterinary products such as vaccines, anthelmintics, antiparasitics, antibiotics, steroids, collars, shampoos and dips.

STORAGE CONDITIONS: Store below 25°C (77°F).

HOW SUPPLIED: Available in eight separate dose strengths for dogs and cats of different weights (see **DOSAGE**). SelaSpot for puppies and kittens is available in cartons containing 3 or 6 single dose tubes. SelaSpot for cats and dogs is available in cartons containing 3 or 6 single dose tubes.

Approved by FDA under ANADA # XXX-XXX

Manufactured by:
Bimeda, Inc.
Le Sueur, MN 56058
www.bimeda.com

N. A. Corp. Address:
Bimeda, Inc.,
One Tower Lane
Oakbrook Terrace, IL 60181

8SEL029 Rev. 09/20



SelaSpot™ is a Trademark of Bimeda, Inc.